Gastric Cancer
Copyright ©The Author(s) 2002. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 15, 2002; 8(6): 1009-1013
Published online Dec 15, 2002. doi: 10.3748/wjg.v8.i6.1009
Expression of gastric cancer-associated MG7 antigen in gastric cancer, precancerous lesions and H. pylori-associated gastric diseases
Dong-Li Guo, Ming Dong, Lan Wang, Li-Ping Sun, Yuan Yuan
Dong-Li Guo, Ming Dong, Lan Wang, Li-Ping Sun, Yuan Yuan, Cancer Institute, First Affiliated Hospital, China Medical University, Shenyang, 110001, Liaoning Province, China
Author contributions: All authors contributed equally to the work.
Supported by The National Basic Research Program (973) of China, No.G1998051203
Correspondence to: Dr. Yuan Yuan, No.3 gastric cancer laboratory, Cancer Institute, First Affiliated Hospital, China Medical University, 155 Northern Nanjing Street, Heping District, Shenyang 110001, Liaoning Province, China. yyuan@mail.cmu.edu.cn
Received: May 13, 2002
Revised: May 28, 2002
Accepted: June 3, 2002
Published online: December 15, 2002
Abstract

AIM: To investigate the relationship between the antigen MG7 antigen expression and gastric cancer as well as precancerous condition; to study the relationship between the MG7 antigen expression and H. pylori infection in benign gastric lesions in order to find out the effect of H. pylori infection on the process of gastric cancer development.

METHODS: The level of MG7 antigen expression was determined by immunohistochemical method in 383 gastric biopsied materials. The intestinal metaplasia was determined by histochemistry method. The H. pylori infection was determined by HE stain, PCR and ELISA in 291 specimens, among which only 34 cases of H. pylori-associated gastric lesions were followed up.

RESULTS: The positive rate of MG7 expression in normal gastric mucosa, intestinal metaplasia, dysplasia and gastric cancer increased gradually in ascending order (P < 0.01). The positive rate of MG7 antigen expression in type III intestinal metaplasia of gastric mucosa was higher than that of type I and II intestinal metaplasia, being highly significant (P < 0.05). The positive rate of MG7 antigen expression in superficial gastritis, atrophic gastritis and gastric cancer increased gradually (11.9%, 64.8%, 91.2%, P < 0.01). There was no significant difference between H .pylori-negative and H. pylori-positive intestinal metaplasia, atrophic gastritis and dysplasia of gastric epithelium in the positive rate of MG7 antigen expression. There was no expression of MG7 antigen in H. pylori-negative superficial gastritis. The positive rate of MG7 expression in H. pylori-positive superficial gastritis was 20.5%, and the difference between them was significant (P < 0.05). During following up, one of the three H. pylori negative cases turned positive again, and its MG7 antigen expression turned to be stronger correspondingly. 3 of 31 H. pylori positive cases were detected as early gastric cancer, among which one with “+++” MG7 antigen expression was diminished after H. pylori eradication.

CONCLUSION: MG7 antigen expression is highly specific in gastric cancer and can be used as a good marker for screening of gastric cancer; type III intestinal metaplasia, atrophic gastritis and dysplasia should be followed up and MG7 antigen expression has high clinical value in the dynamic follow-up study; although the positive -MG7 in positive - H. pylori superficial gastritis show benign morphology in features, there is still the potential risk of developing into gastric cancer, hence special attention should be paid to those showing increasing MG7 antigen expression.

Keywords: $[Keywords]